CN107916236A - 副干酪乳杆菌副干酪亚种k56 - Google Patents
副干酪乳杆菌副干酪亚种k56 Download PDFInfo
- Publication number
- CN107916236A CN107916236A CN201710009845.0A CN201710009845A CN107916236A CN 107916236 A CN107916236 A CN 107916236A CN 201710009845 A CN201710009845 A CN 201710009845A CN 107916236 A CN107916236 A CN 107916236A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- purposes
- composition
- subspecies
- cheese subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 71
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- 230000004054 inflammatory process Effects 0.000 claims abstract description 14
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 235000013351 cheese Nutrition 0.000 claims description 68
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims description 17
- 208000026935 allergic disease Diseases 0.000 claims description 15
- 230000007815 allergy Effects 0.000 claims description 15
- 208000006673 asthma Diseases 0.000 claims description 14
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 claims description 12
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 12
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 12
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 12
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 12
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 102000004388 Interleukin-4 Human genes 0.000 claims description 8
- 108010002616 Interleukin-5 Proteins 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 7
- 102000003816 Interleukin-13 Human genes 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 7
- 102000000743 Interleukin-5 Human genes 0.000 claims description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- 208000028185 Angioedema Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010001889 Alveolitis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims 1
- 241000219422 Urtica Species 0.000 claims 1
- 235000009108 Urtica dioica Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 6
- 235000013365 dairy product Nutrition 0.000 abstract description 5
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 235000019634 flavors Nutrition 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 241000606750 Actinobacillus Species 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 44
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 42
- 210000004681 ovum Anatomy 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000004310 lactic acid Substances 0.000 description 21
- 235000014655 lactic acid Nutrition 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 17
- 210000004241 Th2 cell Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- 108020004465 16S ribosomal RNA Proteins 0.000 description 13
- 101150080777 pheS gene Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 101100311938 Dictyostelium discoideum phesA gene Proteins 0.000 description 7
- 101100423325 Dictyostelium discoideum phesB gene Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 5
- 229960002329 methacholine Drugs 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000003322 glomus cell Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000183331 Lactobacillus paracasei subsp. tolerans Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 241000701836 bacterium K56 Species 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000009531 respiratory rate measurement Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW105132174 | 2016-10-05 | ||
TW105132174A TWI592487B (zh) | 2016-10-05 | 2016-10-05 | 新穎副乾酪乳桿菌副乾酪亞種k56 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107916236A true CN107916236A (zh) | 2018-04-17 |
CN107916236B CN107916236B (zh) | 2020-12-01 |
Family
ID=60048285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710009845.0A Active CN107916236B (zh) | 2016-10-05 | 2017-01-06 | 副干酪乳杆菌副干酪亚种k56 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107916236B (zh) |
TW (1) | TWI592487B (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882280A (zh) * | 2019-06-27 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56的新应用 |
CN110892940A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56在缓解肠道炎症方面的新应用 |
CN110892914A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56改善气喘及相关过敏性症状的新应用 |
CN110903995A (zh) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | 具有促消化功效的益生菌食用组合物及食品 |
WO2020063515A1 (zh) | 2018-09-30 | 2020-04-02 | 内蒙古伊利实业集团股份有限公司 | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 |
CN112640953A (zh) * | 2019-10-10 | 2021-04-13 | 内蒙古伊利实业集团股份有限公司 | 一种具有抗过敏功效的常温酸奶及其制备方法与应用 |
CN112869170A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 |
CN112869167A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用 |
EP3822338A4 (en) * | 2018-09-30 | 2021-08-18 | Inner Mongolia Yili Industrial Group Co., Ltd. | LACTOBACILLUS PARACASEI ET-22 AND USE OF IT |
CN113355375A (zh) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56发酵合成b族维生素的方法及应用 |
CN113712207A (zh) * | 2020-05-21 | 2021-11-30 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
CN114431293A (zh) * | 2020-11-06 | 2022-05-06 | 内蒙古伊利实业集团股份有限公司 | 一种制备乳酸菌饮品的方法和乳酸菌饮品 |
EP4070670A1 (en) * | 2021-04-08 | 2022-10-12 | University College Cork-National University of Ireland Cork | Lacticaseibacillus paracasei em025-11 and uses thereof |
EP3988644A4 (en) * | 2020-08-24 | 2022-11-02 | Byhealth Co., Ltd. | LACTOBACILLUS PARACASEI 207-27 AND ASSOCIATED APPLICATION |
CN116444612A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽apadpgrptgy及其制备方法与应用 |
CN116444610A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽dasaqfir及其制备方法与应用 |
CN116444649A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽gitdplfkgm、gitdplfkg及其获得方法和应用 |
CN116444649B (zh) * | 2022-11-30 | 2024-05-24 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽gitdplfkgm、gitdplfkg及其获得方法和应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019134690A1 (en) * | 2018-01-05 | 2019-07-11 | Bened Biomedical Co., Ltd. | A novel lactic acid bacteria and its applications |
CN110892990B (zh) * | 2019-10-11 | 2023-03-31 | 内蒙古伊利实业集团股份有限公司 | 益生菌益生元食用组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100704A (zh) * | 2010-09-01 | 2011-06-22 | 景岳生物科技股份有限公司 | 益生菌株gm-080用于治疗心脏发炎与心脏细胞凋亡的组合物及其用途 |
CN102399718A (zh) * | 2011-10-14 | 2012-04-04 | 景岳生物科技股份有限公司 | 副干酪乳酸杆菌株gmnl-133、用于改善异位性皮肤炎或其它过敏疾病的组合物及其用途 |
CN104523762A (zh) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | 具有抗过敏作用的副干酪乳杆菌的应用和功能食品组合物及其制备方法 |
CN104894021A (zh) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
CN105748533A (zh) * | 2016-03-11 | 2016-07-13 | 青岛东海药业有限公司 | 副干酪乳杆菌制剂及其应用 |
TW201636035A (zh) * | 2015-04-13 | 2016-10-16 | 聯亞益生生物科技股份有限公司 | 新穎副乾酪乳桿菌副乾酪亞種k66 |
-
2016
- 2016-10-05 TW TW105132174A patent/TWI592487B/zh active
-
2017
- 2017-01-06 CN CN201710009845.0A patent/CN107916236B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100704A (zh) * | 2010-09-01 | 2011-06-22 | 景岳生物科技股份有限公司 | 益生菌株gm-080用于治疗心脏发炎与心脏细胞凋亡的组合物及其用途 |
CN102399718A (zh) * | 2011-10-14 | 2012-04-04 | 景岳生物科技股份有限公司 | 副干酪乳酸杆菌株gmnl-133、用于改善异位性皮肤炎或其它过敏疾病的组合物及其用途 |
CN104523762A (zh) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | 具有抗过敏作用的副干酪乳杆菌的应用和功能食品组合物及其制备方法 |
TW201636035A (zh) * | 2015-04-13 | 2016-10-16 | 聯亞益生生物科技股份有限公司 | 新穎副乾酪乳桿菌副乾酪亞種k66 |
CN104894021A (zh) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
CN104894021B (zh) * | 2015-06-03 | 2018-02-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
CN105748533A (zh) * | 2016-03-11 | 2016-07-13 | 青岛东海药业有限公司 | 副干酪乳杆菌制剂及其应用 |
Non-Patent Citations (4)
Title |
---|
LILLIAN JESPERSEN等: ""Effect of Lactobacillus paracasei subsp.paracase,L.casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunterrrs:a randomized,double-blind,placebo-controlled,parallel-groupe study"", 《THE AMERICAN JOURNAL OF CLINICAL NUTRITION》 * |
周晓丹等: ""副干酪乳杆菌LC-01对便秘小鼠的通便作用"", 《乳业科学与技术》 * |
巨小英等: ""副干酪乳杆菌的功能及其在食品工业中的应用研究进展"", 《中国乳品工业》 * |
庄海霁等: ""副干酪乳杆菌的应用研究进展"", 《生物技术通讯》 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3822338A4 (en) * | 2018-09-30 | 2021-08-18 | Inner Mongolia Yili Industrial Group Co., Ltd. | LACTOBACILLUS PARACASEI ET-22 AND USE OF IT |
EP3811955A4 (en) * | 2018-09-30 | 2021-06-16 | Inner Mongolia Yili Industrial Group Co., Ltd. | NEW USE OF LACTOBACILLUS PARACASEI K56 THAT IS ABLE TO REGULATE THE REST OF THE GASTROINTESTINAL FLORA |
US11274275B2 (en) | 2018-09-30 | 2022-03-15 | Inner Mongolia Yili Industrial Group Co., Ltd. | Lactobacillus paracasei ET-22 and use thereof |
WO2020063515A1 (zh) | 2018-09-30 | 2020-04-02 | 内蒙古伊利实业集团股份有限公司 | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 |
CN110959865A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 |
US11666613B2 (en) * | 2018-09-30 | 2023-06-06 | Inner Mongolia Yili Industrial Group Co., Ltd. | Use of Lactobacillus paracasei subsp. paracasei K56 capable of regulating gastrointestinal flora balance |
CN110882280A (zh) * | 2019-06-27 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56的新应用 |
CN110903995A (zh) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | 具有促消化功效的益生菌食用组合物及食品 |
CN110903995B (zh) * | 2019-09-30 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | 具有促消化功效的益生菌食用组合物及食品 |
CN112640953A (zh) * | 2019-10-10 | 2021-04-13 | 内蒙古伊利实业集团股份有限公司 | 一种具有抗过敏功效的常温酸奶及其制备方法与应用 |
EP4062763A4 (en) * | 2019-11-20 | 2024-01-10 | Inner Mongolia Yili Ind Group | NEW USE OF LACTOBACILLUS PARACASEI K56 FOR RELIEVING INTESTINAL INFLAMMATION |
CN110892914A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56改善气喘及相关过敏性症状的新应用 |
CN110892940A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56在缓解肠道炎症方面的新应用 |
CN112869168B (zh) * | 2019-11-29 | 2023-06-06 | 内蒙古伊利实业集团股份有限公司 | 可提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
CN112869168A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 可提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
CN112869170A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 |
CN112869167A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用 |
CN113712207B (zh) * | 2020-05-21 | 2023-06-06 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
CN113712207A (zh) * | 2020-05-21 | 2021-11-30 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
EP3988644A4 (en) * | 2020-08-24 | 2022-11-02 | Byhealth Co., Ltd. | LACTOBACILLUS PARACASEI 207-27 AND ASSOCIATED APPLICATION |
JP7263622B2 (ja) | 2020-08-24 | 2023-04-24 | バイヘルス・カンパニー,リミテッド | Lactobacillus paracasei 207-27およびその使用 |
JP2022550933A (ja) * | 2020-08-24 | 2022-12-06 | バイヘルス・カンパニー,リミテッド | Lactobacillus paracasei 207-27およびその使用 |
US11812770B2 (en) | 2020-08-24 | 2023-11-14 | BYHEALTH Co., Ltd. | Lactobacillus paracasei 207-27 and use thereof |
CN114431293A (zh) * | 2020-11-06 | 2022-05-06 | 内蒙古伊利实业集团股份有限公司 | 一种制备乳酸菌饮品的方法和乳酸菌饮品 |
CN113355375A (zh) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56发酵合成b族维生素的方法及应用 |
WO2022214700A1 (en) * | 2021-04-08 | 2022-10-13 | University College Cork - National University Of Ireland, Cork | Lacticaseibacillus paracasei em025-11 and uses thereof |
EP4070670A1 (en) * | 2021-04-08 | 2022-10-12 | University College Cork-National University of Ireland Cork | Lacticaseibacillus paracasei em025-11 and uses thereof |
CN116444612A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽apadpgrptgy及其制备方法与应用 |
CN116444610A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽dasaqfir及其制备方法与应用 |
CN116444649A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽gitdplfkgm、gitdplfkg及其获得方法和应用 |
CN116444610B (zh) * | 2022-11-30 | 2024-05-17 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽dasaqfir及其制备方法与应用 |
CN116444649B (zh) * | 2022-11-30 | 2024-05-24 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽gitdplfkgm、gitdplfkg及其获得方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
TWI592487B (zh) | 2017-07-21 |
CN107916236B (zh) | 2020-12-01 |
TW201814039A (zh) | 2018-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107916236A (zh) | 副干酪乳杆菌副干酪亚种k56 | |
CN104894021B (zh) | 一种副干酪乳杆菌及其应用 | |
CN104862241B (zh) | 具有免疫调节及抗过敏功效的乳酸菌及包含该乳酸菌的医药组合物 | |
CN104480032B (zh) | 一株具有增强免疫活性的植物乳杆菌 | |
CN114317320B (zh) | 一种短双歧杆菌207-1及其应用 | |
CN113913322B (zh) | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 | |
US11260085B2 (en) | Salt-tolerant lactobacillus, method of culturing salt-tolerant lactobacillus, and immunostimulant | |
CN114181864B (zh) | 一种鼠李糖乳杆菌hf01及其应用 | |
CN103550258B (zh) | 乳酸菌株调节免疫反应的用途 | |
JP2007117031A (ja) | インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌 | |
CN109666614A (zh) | 一种鼠李糖乳杆菌及其在制备预防过敏性哮喘的保健食品和药品中的应用 | |
TWI509069B (zh) | 具有免疫調節及抗過敏作用的乳酸菌 | |
JP7358002B2 (ja) | バチルス属細菌、インターロイキン-22産生誘導剤、皮膚バリア機能増強剤 | |
TW201636035A (zh) | 新穎副乾酪乳桿菌副乾酪亞種k66 | |
TWI429444B (zh) | 新穎乳酸菌株及其調節免疫反應的用途 | |
US20110052553A1 (en) | Strain of lactobacillus plantarum lp28 and its use in treating hypersensitivity reactions | |
CN113462616A (zh) | 一株人源鼠李糖乳杆菌glr8及其制备方法 | |
CN117159598B (zh) | 植物乳植杆菌Lp18在制备增强免疫的药物或保健食品方面的用途及产品 | |
Kim et al. | In vitro characterization study of Bacillus mojavensis KJS-3 for a potential probiotic | |
CN117448243B (zh) | 一株具有益生功能且能增强免疫的嗜粘蛋白阿克曼氏菌Akk007及其应用与保健品 | |
CN114395514B (zh) | 一株嗜酸乳杆菌、菌剂及其应用 | |
CN117917475A (zh) | 一种调节肠道菌群的植物乳植杆菌p16及其应用、产品和方法 | |
TWI667031B (zh) | 具有免疫調節及抗過敏功效之乳酸菌及包含該乳酸菌之醫藥組成物 | |
CN117143781A (zh) | 植物乳杆菌、Mix后生元及其制备方法与应用 | |
CN114540236A (zh) | 一株发酵乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180416 Address after: 1 Jinshan street, Jinshan Development Area, Hohhot, the Inner Mongolia Autonomous Region Applicant after: Yili Ind Co., Ltd., Inner Mongolia Address before: Taipei City, Taiwan, China Applicant before: Yi Fusheng medicine Limited by Share Ltd |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20180417 Assignee: Inner Mongolia Yili Industrial Group Co.,Ltd. Jinshan Branch Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2021990000637 Denomination of invention: Lactobacillus paracasei subspecies K56 Granted publication date: 20201201 License type: Common License Record date: 20211019 Application publication date: 20180417 Assignee: Inner Mongolia yijiahao cheese Co.,Ltd. Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2021990000638 Denomination of invention: Lactobacillus paracasei subspecies K56 Granted publication date: 20201201 License type: Common License Record date: 20211019 |